1. Understanding the biology of HER3 receptor as a therapeutic target in human cancer
- Author
-
Shuang Liu, Amy Han, Erik V. Polsdofer, Bolin Liu, and Hui Lyu
- Subjects
0301 basic medicine ,lncRNA, long ncRNA ,Cell signaling ,medicine.medical_treatment ,Review ,Ab, antibody ,TKI, tyrosine kinase inhibitor ,Receptor tyrosine kinase ,Targeted therapy ,IGF-1R, insulin-like growth factor-I receptor ,0302 clinical medicine ,ADCC, antibody-dependent cell-mediated cytotoxicity ,miRNA, microRNA ,General Pharmacology, Toxicology and Pharmaceutics ,skin and connective tissue diseases ,ERBB4 ,biology ,3. Good health ,030220 oncology & carcinogenesis ,RTK, receptor tyrosine kinase ,EMT, epithelial-mesenchymal transition ,Tyrosine kinase ,Dimerization ,Proto-oncogene tyrosine-protein kinase Src ,PI-3K, phosphoinositide 3-kinase ,OS, overall survival ,03 medical and health sciences ,HER3 ,NSCLC, non-small cell lung cancer ,medicine ,PI3K/AKT/mTOR pathway ,lcsh:RM1-950 ,MEK, MAPK kinase ,Cancer ,Therapeutic resistance ,HER, Human epidermal growth factor receptor ,medicine.disease ,FDA, Food and Drug Administration ,EGFR, epidermal growth factor receptor ,body regions ,030104 developmental biology ,lcsh:Therapeutics. Pharmacology ,biology.protein ,Cancer research ,HRG, heregulin ,MAPK, mitogen-activated protein kinase ,Tumor metastasis ,ncRNA, noncoding RNA - Abstract
HER3 belongs to the human epidermal growth factor receptor (HER) family which also includes HER1/EGFR/erbB1, HER2/erbB2, and HER4/erbB4. As a unique member of the HER family, HER3 lacks or has little intrinsic tyrosine kinase activity. It frequently co-expresses and forms heterodimers with other receptor tyrosine kinases (RTKs) in cancer cells to activate oncogenic signaling, especially the PI-3K/Akt pathway and Src kinase. Elevated expression of HER3 has been observed in a wide variety of human cancers and associates with a worse survival in cancer patients with solid tumors. Studies on the underlying mechanism implicate HER3 expression as a major cause of treatment failure in cancer therapy. Activation of HER3 signaling has also been shown to promote cancer metastasis. These data strongly support the notion that therapeutic inactivation of HER3 and/or its downstream signaling is required to overcome treatment resistance and improve the outcomes of cancer patients., Graphical abstract HER3 belongs to the human epidermal growth factor receptor (HER) family. HER3 lacks or has little intrinsic tyrosine kinase activity, but it frequently co-expresses and forms heterodimers with other receptor tyrosine kinases (RTKs) to activate oncogenic signaling in cancer cells. Therapeutic inactivation of HER3 and/or its downstream signaling is required to overcome treatment resistance and improve the outcomes of cancer patients.fx1
- Published
- 2018